Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.300
-0.180 (-5.17%)
At close: Feb 20, 2026, 4:00 PM EST
3.350
+0.050 (1.52%)
After-hours: Feb 20, 2026, 4:00 PM EST
Evaxion Employees
Evaxion had 46 employees as of December 31, 2024. The number of employees decreased by 3 or -6.12% compared to the previous year.
Employees
46
Change (1Y)
-3
Growth (1Y)
-6.12%
Revenue / Employee
$166,304
Profits / Employee
-$117,783
Market Cap
27.44M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 46 | -3 | -6.12% |
| Dec 31, 2023 | 49 | -14 | -22.22% |
| Dec 31, 2022 | 63 | 2 | 3.28% |
| Dec 31, 2021 | 61 | 26 | 74.29% |
| Dec 31, 2020 | 35 | -1 | -2.78% |
| Sep 30, 2020 | 32 | -4 | -11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| Boundless Bio | 64 |
| Passage Bio | 60 |
| Cue Biopharma | 41 |
| Lantern Pharma | 24 |
| AN2 Therapeutics | 22 |
| Rallybio | 15 |
| Hyperion DeFi | 14 |
EVAX News
- 5 weeks ago - Evaxion expands AI-Immunology™ platform into autoimmune diseases - GlobeNewsWire
- 6 weeks ago - Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week - GlobeNewsWire
- 2 months ago - Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Benzinga
- 2 months ago - Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 - GlobeNewsWire
- 2 months ago - Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting - GlobeNewsWire
- 3 months ago - Evaxion announce 2026 financial calendar - GlobeNewsWire
- 3 months ago - Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 - GlobeNewsWire
- 3 months ago - Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript - Seeking Alpha